249 related articles for article (PubMed ID: 27491146)
1. [EFFICACY OF STANDARD TWO-YEAR COMPREHENSIVE THERAPY TO ACHIEVE TARGET BLOOD PRESSURE AND REGRESSION DEGREES OF REMODELING OF THE LEFT VENTRICULAR HYPERTROPHY IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION WITH COMORBID HYPERTENSION].
Denesiuk EV
Lik Sprava; 2015; (7-8):22-9. PubMed ID: 27491146
[TBL] [Abstract][Full Text] [Related]
2. [THE EFFECTIVENESS OF THE CORRECTION OF ENDOTHELIAL DYSFUNCTION AND REMODELING OF THE BRACHIAL ARTERY WITH CONCENTRIC AND ECCENTRIC LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH UNSTABLE ANGINA WITH COMORBID HYPERTENSION].
Denesiuk EV
Lik Sprava; 2015; (5-6):72-6. PubMed ID: 27089719
[TBL] [Abstract][Full Text] [Related]
3. [REGRESSION OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ESSENTIAL HYPERTENSION AND LONG-TERM THERAPY WITH LOSARTAN].
Dotsenko SY; Tokarenko AA; Tokarenko II
Lik Sprava; 2015; (7-8):17-21. PubMed ID: 27491145
[TBL] [Abstract][Full Text] [Related]
4. Effects of angiotensin II receptor blockade-based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients.
Cuspidi C; Meani S; Valerio C; Fusi V; Sala C; Maisaidi M; Zanchetti A
Blood Press; 2006; 15(2):107-15. PubMed ID: 16754274
[TBL] [Abstract][Full Text] [Related]
5. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Bang CN; Gerdts E; Aurigemma GP; Boman K; de Simone G; Dahlöf B; Køber L; Wachtell K; Devereux RB
Circ Cardiovasc Imaging; 2014 May; 7(3):422-9. PubMed ID: 24723582
[TBL] [Abstract][Full Text] [Related]
6. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
[TBL] [Abstract][Full Text] [Related]
7. Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy.
Gerdts E; Okin PM; Boman K; Wachtell K; Nieminen MS; Dahlöf B; Devereux RB
Am J Hypertens; 2012 Jun; 25(6):678-83. PubMed ID: 22456225
[TBL] [Abstract][Full Text] [Related]
8. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS).
Farsang C; Lengyel M; Borbás S; Zorándi A; Dienes BS;
Curr Med Res Opin; 2003; 19(3):205-17. PubMed ID: 12803735
[TBL] [Abstract][Full Text] [Related]
9. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
[TBL] [Abstract][Full Text] [Related]
10. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Nordestgaard BG; Kontula K; Benn M; Dahlöf B; de Faire U; Edelman JM; Eliasson E; Fyhrquist F; Hille DA; Ibsen H; Lyle PA; Berg K; Sandberg M; Sethi AA; Wong PH; Os I
Pharmacogenet Genomics; 2010 Feb; 20(2):77-85. PubMed ID: 20065889
[TBL] [Abstract][Full Text] [Related]
11. Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study.
Boman K; Gerdts E; Wachtell K; Dahlöf B; Nieminen MS; Olofsson M; Papademetriou V; Devereux RB
Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):242-8. PubMed ID: 19369828
[TBL] [Abstract][Full Text] [Related]
12. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
[TBL] [Abstract][Full Text] [Related]
13. Incremental prognostic value of a complex left ventricular remodeling classification in asymptomatic for heart failure hypertensive patients.
Fabiani I; Pugliese NR; La Carrubba S; Conte L; Antonini-Canterin F; Colonna P; Benedetto F; Calogero E; Barletta V; Carerj S; Buralli S; Taddei S; Romano MF; Di Bello V;
J Am Soc Hypertens; 2017 Jul; 11(7):412-419. PubMed ID: 28619598
[TBL] [Abstract][Full Text] [Related]
14. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
[TBL] [Abstract][Full Text] [Related]
15. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
16. Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
Gerdts E; de Simone G; Lund BP; Okin PM; Wachtell K; Boman K; Nieminen MS; Dahlöf B; Devereux RB
Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):122-9. PubMed ID: 21775111
[TBL] [Abstract][Full Text] [Related]
17. Losartan reduces left ventricular hypertrophy proportionally to blood pressure reduction in hypertensives, but does not affect diastolic cardiac function.
Zakynthinos E; Pierutsakos Ch; Konstantinidis K; Zakynthinos S; Papadogiannis D
Angiology; 2004; 55(6):669-78. PubMed ID: 15547653
[TBL] [Abstract][Full Text] [Related]
18. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Kjeldsen SE; Devereux RB; Hille DA; Lyle PA; Dahlöf B; Julius S; Edelman JM; Snapinn SM; de Faire U; Fyhrquist F; Ibsen H; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Blood Press; 2009; 18(6):348-61. PubMed ID: 20001655
[TBL] [Abstract][Full Text] [Related]
19. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
[TBL] [Abstract][Full Text] [Related]
20. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
